Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

NCT06261840

Status	RECRUITING
Phase	Phase 4
Sponsor	Tulane University
Enrollment	1,200 participants

Key Eligibility Criteria

Inclusion (5)

- Women and men aged 18 years or older of any race/ethnicity will be included in the study.
- Participants must have either a positive T. vaginalis rapid antigen test (OSOM), or wet mount microscopy with motile trichomonads, or nucleic acid amplification test (NAAT) urinalysis or Pap smear positive for TV within two weeks of available results (and have not yet been treated) that is confirmed by repeat T. vaginalis NAAT testing at study enrollment,
- Willing and able to provide and understand informed consent to comply with the study protocol,
- Have a method of contact (either phone, email or social media),
- Be willing to be randomized.

Exclusion (7)

- Pregnant/lactating or seeking to be pregnant
- Have been treated for with a 5-nitroimidazole (i.e. Metronidazole (MTZ), tinidazole (TDZ), or secnidazole \[SEC\]) in the last 28 days
- Used intravaginal boric acid or any other intravaginal treatment for T. vaginalis in the last 14 days
- Have a history of a type 1 hypersensitivity reaction to 5-nitroimidazole medications
- Are taking phenytoin (Dilantin) and/or warfarin (Coumadin) due to drug-drug interactions with oral MTZ

... and 2 more (see full listing online)

Locations (4 total)

University of Alabama at Birmingham [UAB] Gynecology Clinics, Birmingham, Alabama, United States
UAB Sexual Health Research Clinic [SHRC], Birmingham, Alabama, United States
Segal Trials Healthcare Clinical Data, Inc. 1065 NE 125th St. Suite 417 North Miami, FL 33161, North Miami, Florida, United States
... and 1 more locations